Introduction
============

With the aging and growth of population as well as the prevalence of established risk factors, cancer incidence and mortality have been increasing.[@b1-ott-11-4491] GLOBOCAN 2012 data shows lung cancer remains the first leading cause of cancer-related death in male patients worldwide. In female patients of more developed countries, it has even surpassed breast cancer to be the leading cause of cancer death.[@b1-ott-11-4491] There is no doubt that cancer will create a giant burden on societies in the following decades.

In a recent study, it is found that adjuvant gefitinib can significantly prolong the disease-free survival (28.7 vs 18.0 months, *P*=0.0054) of resected stage II--III *EGFR*-mutant non-small-cell lung cancer compared with traditional chemotherapy. Its impact on overall survival (OS) need to be further studied because the OS data are not yet mature.[@b2-ott-11-4491] Studies involving Nivolumab (*PD-1* inhibitor) have achieved great success and the results show that Nivolumab can significantly improve the OS of lung cancer patients with a favorable safety profile.[@b3-ott-11-4491]--[@b5-ott-11-4491] Lung cancer treatment has become more and more standardized and patients may have more chances of being treated with variable treatment strategies. However, the prognosis of lung cancer remains unsatisfactory, with a 5-year survival rate of \<10%.[@b6-ott-11-4491] Treatment strategies with high efficiency and low toxicity are urgently needed.

Immunotherapy has been an active area in cancer research in recent years. However, the identification of ideal targets is the main point restricting the study of immunotherapy. Cancer/testis antigens (CTAs) are considered ideal targets for cancer treatment due to their high immunogenic, restricted expression in germ cells and malignancies.[@b7-ott-11-4491]--[@b9-ott-11-4491] Generally, germ cells do not express human leukocyte antigen (HLA) class I molecules, leading them escape from the attack of T cells. Though somatic tissues, such as thyroid, breast, and retina may have the expression of CTAs, their expression is far below that in testis tissue and their function remains to be discovered. CTA-induced immunotherapy can specifically identify and kill cancer cells expressing corresponding CTAs, while they have limited toxicities on patients at the same time.[@b10-ott-11-4491]--[@b12-ott-11-4491]

One important point needing to be considered when selecting ideal targets for immunotherapy is the expression frequency of CTAs. Our previous study (unpublished data) shows that *MAGEA1*, *MAGEA10*, *MAGEB2*, *KK-LC-1*, and *CTAG1A*/*B* have a high expression rate in lung cancer samples. Increasing evidence has demonstrated that CTAs play important roles in oncogenesis, including sustained growth, angiogenesis, evading apoptosis, invasion, metastasis, and so on. *MAGEA*, *MAGEB*, and *MAGEC* families have been demonstrated to promote cancer cells survival and inhibit apoptosis through the binding and regulation of tumor suppressor p53.[@b13-ott-11-4491] CTAs, including *CTAG1B* (*NY-ESO-1*), *SSX*, and so on also play a key role in tumor invasion and metastasis.[@b14-ott-11-4491] *MAGEA1* and *CTAG1B* show higher expression frequencies in metastatic melanoma compared with primary tumor.[@b15-ott-11-4491],[@b16-ott-11-4491] *KK-LC-1* is a novel CTA that was first identified in human lung cancer, and is also expressed in a wide range of malignancies.[@b17-ott-11-4491] CTAs expression is heterogeneous and their expression has significant regional and racial distinctions.[@b9-ott-11-4491],[@b18-ott-11-4491]--[@b23-ott-11-4491] In this study, we aim to analyze the expression rate of the aforementioned 5 CTAs and explore their relationship with clinical features in resected lung cancer patients of China.

Patients and methods
====================

Patients and specimens
----------------------

This study used 38 lung cancer samples for real-time polymerase chain reaction (RT-PCR). All patients had pathologically confirmed lung cancer and the tissues were surgically obtained at our hospital between May 2013 and August 2013. Our study was approved by the Ethics Committee of Harbin Medical University Cancer Hospital and written informed consent was obtained from each patient. The tumor stage was classified based on the eighth edition of lung cancer stage classification.[@b24-ott-11-4491]

Quantitative real time-PCR
--------------------------

Five relative high expressed CTAs (*MAGEA1*, *MAGEA10*, *MAGEB2*, *KK-LC-1*, and *CTAG1A*/*B*) in our pre-study were selected to examine their expression at mRNA level. Total RNA from lung cancer frozen tissue specimens was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Complementary DNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 20 μL. RT-PCR was performed using SYBR Green Master Mix (Roche Applied Science, Mannheim, Germany) and QuantStudio^®^ 3 Thermo Fisher (Applied Biosystems). β-actin was used as the internal control. The primers were synthesized by Oligo-fectamine (Invitrogen, San Diego, CA, USA). There were no nonspecific amplification products observed in any of the reactions based on the analysis of the dissociation curves. Each RT-PCR experiment was repeated 3 times. Ct represents the threshold cycle. The data were normalized to the β-actin expression levels, which was named ∆Ct value. The sample with the largest *MAGEA1*, *MAGEA10*, *MAGEB2*, *KK-LC-1*, and *CTAG1A*/*B* ∆Ct was used as control and the relative gene expression levels were calculated using the comparative Ct (∆∆Ct) method. The relative expression was calculated as 2^−∆∆Ct^. High or low CTAs expression was determined by a receiver operating characteristic (ROC) curve analysis according to the lymph node metastasis status at diagnosis (patients with lymph node metastasis at diagnosis were registered as 1, otherwise 0). Youden index was calculated as (sensitivity + specificity −1). The optimal cut-off value was determined as CTA expression with the largest Youden index. High expression was determined as CTA expression larger than the optimal cut-off value, and low expression as CTA expression lower than the optimal cut-off value. The primer sets are seen in [Table 1](#t1-ott-11-4491){ref-type="table"}.

The Cancer Genome Atlas (TCGA) data
-----------------------------------

RNA-seq data of these CTAs for lung cancer and corresponding clinical information were downloaded from the TCGA database. Patients with missing clinicopathological data, including age, gender, tumor stage, OS, and survival status were excluded. High and low CTAs (*MAGEA1*, *MAGEA10*, *MAGEB2*, and *KK-LC-1*) expression was also determined by ROC curve analysis used previously. However, in total cases, only few patients in TCGA database expressed *CTAG1A* (n=106) and *CTAG1B* (n=43), and the relative expression levels were low, especially in lung squamous cell carcinoma (SCC) patients. Patients with *CTAG1A* and *CTAG1B* relative expression levels \>0 were registered as high expression, whilst those with levels ≤0 were registered as low expression.

Statistical analysis
--------------------

The OS time was defined from diagnosis to death or the last follow-up if the patients were still alive. The survival curves and 95% CIs were obtained using the Kaplan--Meier method, and the survival in different groups was compared by log-rank tests. The relationships between CTAs and clinicopathological features were assessed by the chi-squared test. The univariate analysis was used to evaluate the potential prognostic role of variables. The prognostic factors with *P*-values \<0.05 in the univariate analysis were examined in the multivariate analysis. SPSS 16.0 statistical software was used for statistical analysis. All *P*-values \<0.05 were considered statistically significant.

Results
=======

Patient characteristics
-----------------------

The patient characteristics are listed in [Table 2](#t2-ott-11-4491){ref-type="table"}. The mean age for all cases was 56.53±7.76 years (range 32--71). Most patients were male (68.4%, n=26) with an age of \<60 years at diagnosis (63.2%, n=24). Over half of the patients (68.4%, n=26) had a smoking history. Twenty patients (52.6%) had lymph node metastasis at diagnosis. The TNM stage for all patients was listed as stage I (36.8%, n=14), II (31.6%, n=12), and III (31.6%, n=12). The main pathological types were adenocarcinoma (ADC, 50%, n=19), SCC (34.2%, n=13), and others (15.8%, n=6). There were 16 (42.1%) and 3 (7.9%) patients receiving the treatment of postoperative adjuvant chemotherapy and radiotherapy, respectively.

CTAs expression
---------------

The optimal cut-off value for 5 CTAs based on ROC analysis result was as follows: 2,391.75 for *MAGEA1* (AUC=0.739; 95% CI: 0.580--0.897; *P*=0.012), 27.64 for *MAGEA10* (AUC=0.667; 95% CI: 0.492--0.841; *P*=0.079), 16.11 for *MAGEB2* (AUC=0.694; 95% CI: 0.524--0.895; *P*=0.041), 6,199.82 for *KK-LC-1* (AUC=0.667; 95% CI: 0.492--0.841; *P*=0.079), and 178.85 for *CTAG1A*/*B* (AUC=0.594; 95% CI: 0.409--0.780; *P*=0.320), respectively. High expression of *MAGEA1*, *MAGEA10*, *MAGEB2*, *KK-LC-1*, and *CTAG1A*/*B* was found in 16 (42.1%), 30 (79.0%), 29 (76.3%), 14 (36.8%), and 26 (68.4%) cases, respectively.

The relationships between CTAs expression and patient characteristics
---------------------------------------------------------------------

Clinicopathological features, including gender, age, smoking history, pathological T stage, pathological N stage, TNM stage, and pathological types were chosen to compare their relationship with CTAs expression. High expression of *MAGEA1* (N0 vs N1--2, 16.7% vs 65.0%, *P*=0.004), *MAGEA10* (N0 vs N1--2, 61.1% vs 95.0%, *P*=0.016), *MAGEB2* (N0 vs N1--2, 55.6% vs 95.0%, *P*=0.007), and *KK-LC-1* (N0 vs N1--2, 16.7% vs 55.0%, *P*=0.020) was closely correlated with lymph node metastasis at diagnosis. Although the difference was not statistically significant, *CTAG1A*/*B* expression also had a similar trend (N0 vs N1--2, 55.6% vs 80.0%, *P*=0.164). High CTAs expression was seen in patients with pathological N1--2 stage. Additionally, high *MAGEA10* (I vs II + III, 57.1% vs 91.7%, *P*=0.034) and *KK-LC-1* (I vs II + III, 14.3% vs 50.0%, *P*=0.039) expression were associated with advanced TNM stage ([Table 3](#t3-ott-11-4491){ref-type="table"}). Although no statistical significance was found in the rest 3 CTAs, they all had a similar trend that CTAs had a higher expression rate in patients with advanced stage. In addition, patients with age ≥60 years had a higher *CTAG1A*/*B* expression rate compared with patients with age \<60 years (54.2% vs 92.9%, *P*=0.027). There was no significant difference found between CTAs expression and gender, smoking history, pathological T stage, and pathological types.

CTAs expression and OS
----------------------

The prognostic roles of all variables in [Table 2](#t2-ott-11-4491){ref-type="table"} and 5 CTAs expression were tested to evaluate their potential prognostic values. The 3 years survival rate for patients with high and low *MAGEB2* expression was 58.2% and 100.0% (*P*=0.033), respectively. The 3 years survival rate for patients with high and low *CTAG1A*/*B* expression was 53.6% and 100.0% (*P*=0.009), respectively. High expression of *MAGEB2* and *CTAG1A*/*B* were correlated with unfavorable prognosis ([Figure 1](#f1-ott-11-4491){ref-type="fig"}). The 3 years survival rates of patients with high *MAGEA1*, *MAGEA10*, and *KK-LC-1* expressions were 59.2%, 63.3%, and 68.8%, compared with 75.6%, 87.5%, and 68.9% in patients with low corresponding CTAs expression. The expression of *MAGEA1*, *MAGEA10*, and *KK-LC-1* did not have significant association with the prognosis (*P*\>0.05). In addition, N stage (*P*=0.023) and TNM stage (*P*=0.026) were also closely correlated with OS on univariate analysis. No significant survival difference was found in age, gender, smoking history, T stage, pathological types, chemotherapy, and radiotherapy. No variables held statistical significance on multivariate analysis (*P*\>0.05). Our results showed that *MAGEB2* and *CTAG1A*/*B* expression was associated with the prognosis of resected lung cancer patients, but they were not independent prognostic factors.

Subgroup analysis of CTAs expression and OS
-------------------------------------------

Given CTAs showed a significant higher expression in patients with stage II and III, subgroup analysis based on TNM stage was performed to assess the potential prognostic roles of CTAs expression on selected patients. The variables evaluated were just the same with the analysis for all cases. When the analysis was limited to patients with stage II and III, only high expression of *CTAG1A*/*B* also had a negative impact on survival ([Figure 2](#f2-ott-11-4491){ref-type="fig"}, *P*=0.031).

Subgroup analysis based on variable pathological types showed that only pathological N stage (*P*=0.019) and TNM stage (*P*=0.038) were closely associated with the prognosis of ADC patients, while no clinicopathological characteristics were associated with the prognosis of non-ADC patients (*P*\>0.05). Although no statistical significance was found between CTAs expression and OS of lung ADC and non-ADC patients, high *CTAG1A*/*B* expression also had a similar prognostic trend in ADC (*P*=0.052) and non-ADC cases (*P*=0.100).

Validation of CTAs expression in TCGA database
----------------------------------------------

A total of 962 cases (479 ADC and 483 SCC) in TCGA database were enrolled to validate the aforementioned results in our study. The potential prognostic parameters included pathological types (ADC vs SCC), age (\<60 vs ≥60 years), gender (male vs female), tumor stage (I + II vs III + IV), T stage (T1--2 vs T3--4), N stage (N0 vs N1--3) and CTAs expression. For total cases, only tumor stage (*P*\<0.001) T (*P*\<0.001) and N (*P*\<0.001) were closely associated with OS on univariate analysis, while no CTAs expression was correlated with OS (*P*\>0.05). When all parameters were evaluated in multivariate analysis, only T stage (hazard ratio \[HR\]=1.525, 95% CI: 1.131--2.057, *P*=0.006) and N stage (HR=1.438, 95% CI: 1.131--1.828, *P*=0.003) held statistical significance.

Subgroup analysis was also performed based on variable pathological types. In ADC patients, tumor stage (*P*\<0.001), T stage (*P*\<0.001), N stage (*P*\<0.001), and *CTAG1B* (*P*=0.047) were closely associated with the prognosis of patients on univariate analysis ([Figure 3](#f3-ott-11-4491){ref-type="fig"}). When all parameters were evaluated in multivariate analysis, *MAGEA1* (HR=1.487, 95% CI: 1.006--2.197, *P*=0.046), *CTAG1B* (HR=2.733, 95% CI: 1.348--5.541, *P*=0.005), T stage (HR=1.820, 95% CI: 1.170--2.829, *P*=0.008), and N stage (HR=2.246, 95% CI: 1.564--3.224, *P*\<0.001) were all found to be independent prognostic factors of lung ADC patients. In SCC patients, only tumor stage (*P*=0.012) and T stage (*P*=0.004) were closely associated with the prognosis of patients, and no parameters were found to have statistical significance on multivariate analysis.

Discussion
==========

In our study, we found that high expression rate of these 5 CTAs ranged 36.8%--79.0%. CTAs expression at mRNA level was closely associated with pathological N and TNM stages. Patients with stage II--III and lymph node metastasis had a higher CTAs expression rate compared with patients with stage I and no lymph node metastasis. In addition, *CTAG1A*/*B* expression had a negative impact on OS of resected lung cancer patients. TCGA database analysis showed that the negative prognostic role of *CTAG1A*/*B* was mainly induced by *CTAG1B*, and high *CTAG1B* expression was an independent prognostic factor of lung ADC cases.

More and more attention has been paid to the study of immunotherapy and targeted therapy due to the limited benefits of conventional chemotherapy and the associated toxicities.[@b2-ott-11-4491] CTAs represent potential candidates for the management of cancers due to their restricted expression in cancer and immune-privileged tissues, such as testis and placenta. These immune-privileged tissues cannot present CTAs because of the lacking expression of HLA class I molecules, and this leads to the escape of effector T cell attack. Previous studies have demonstrated the anti-tumor effect of immunotherapy.[@b10-ott-11-4491]--[@b12-ott-11-4491],[@b25-ott-11-4491] Immunotherapy has 2 significant benefits. On the one hand, if immunotherapy shows great advantages over conventional therapies, patients can benefit more from treatment with immunotherapy. On the other hand, if immunotherapy has as much effect as conventional therapies, that is also good for patients because the toxicities of immunotherapy are usually less. Both the conditions have significant effect on cancer patients.

One notable characteristic of CTAs is their heterogeneity in variable malignancies. Lung cancer belongs to CTA-rich cancers due to its high frequency of CTAs expression. The frequency of 5 tested CTAs in our study varies largely, ranging 36.8%--79.0%. Regional and racial difference may influence CTAs expression. The *KK-LC-1* (36.8% vs 33.0%) and *MAGEA1* (42.1% vs 31.0%) expression is similar with previous studies, while the *MAGEA10* (79.0% vs 28.0%) expression varies largely with previous studies.[@b22-ott-11-4491],[@b26-ott-11-4491] In our study, *MAGEB2* and *CTAG1A*/*B* expression frequency represents 76.3% and 68.4%, which is higher than that in TCGA database. The majority of patients involved in TCGA database were White (n=722), Black and African American (n=79), American Indian (n=1), and unknown origins (n=145), while only 15 cases were of Asian origin. The TCGA database shows that *CTAG1A* (13.3% vs 11.0%) and *CTAG1B* (6.7% vs 4.4%) expression in Asians was higher than non-Asian race. All patients enrolled in our study were of Asian origin, and CTAs expression heterogeneity was significant in variable race.

In our study, CTAs expression was closely associated with pathological lymph node metastasis and advanced tumor stage. Patients with stage II and III show a higher CTAs expression compared with patients with stage I, and this is similar with previous studies.[@b22-ott-11-4491],[@b27-ott-11-4491] We also find that patients with lymph node metastasis have a higher CTAs expression frequency compared with patients without lymph node metastasis. A previous study demonstrates that *MAGEC1* and *MAGEC2* expression can independently predict lymph node metastasis.[@b28-ott-11-4491] More lymph node metastases are found in patients with positive expression of *MAGEC1* and *MAGEC2*, which is in favor of our results.

Cancer stem cells (CSCs) play an important role in cancer invasion and metastasis.[@b29-ott-11-4491] Previous studies have demonstrated that several CTAs involving *MAGEB2* and *NY-ESO-1* (*CTAG1B*) show preferential expression in CSCs compared with non-CSCs.[@b30-ott-11-4491] They can be regarded as cancer/testis/stem genes, which are closely associated with the progress of tumor migration, invasion, and the formation of secondary metastatic lesions.[@b14-ott-11-4491],[@b31-ott-11-4491],[@b32-ott-11-4491] In our study, the results show that *MAGEB2* and *CTAG1A*/*B* are closely correlated with the prognosis of resected lung cancer patients. In subgroup analysis, *CTAG1A*/*B* expression still shows unfavorable prognosis in patients with stage II and III. This can be partly interpreted by the theory mentioned previously. The TCGA database analysis shows that the negative prognostic role of *CTAG1A*/*B* is mainly induced by *CTAG1B*, and high *CTAG1B* expression is an independent negative prognostic factor of lung ADC patients. Unfortunately, the role of *MAGEB2* is not confirmed by TCGA database analysis.

Our study aims at exploring CTAs expression frequency at mRNA level in resected lung cancer and analyzes their relationship with clinicopathological characteristics. There are some limitations of our study. First, the surgical samples in our study are only 38 and the results need to be demonstrated in larger samples. Second, we do not assess the CTAs expression at protein level due to the lack of enough samples. In addition, there may be some limitations present due to the retrospective features of our study.

Conclusion
==========

In summary, high *MAGEA1*, *MAGEA10*, *MAGEB2*, *KK-LC-1*, and *CTAG1A*/*B* expression at mRNA level range is 36.8%--79.0%. CTAs represent potential candidates for cancer immunotherapy and their expression is closely associated with pathological lymph node metastasis and tumor stage. High *CTAG1A*/*B* expression is a negative prognostic factor in resected lung cancer patients, and its negative role is mainly induced by *CTAG1B* based on TCGA database analysis. High *CTAG1B* expression is an independent negative prognostic factor of lung ADC patients.
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![Overall survival curves of all patients according to CTAs expression.\
**Note:** High *MAGEB2* and *CTAG1A/B* expression showed poorer prognosis than low expression (*P*\<0.05), while the expression of the other 3 CTAs showed no significant correlations with survival (*P*\>0.05).\
**Abbreviation:** CTAs, cancer/testis antigens.](ott-11-4491Fig1){#f1-ott-11-4491}

![Overall survival curve of patients with pathological stage II and III according to CTAs expression.\
**Note:** In patients with stage II and III, high expression of *CTAG1A/B* showed poorer prognosis than low expression (*P*=0.031).\
**Abbreviation:** CTAs, cancer/testis antigens.](ott-11-4491Fig2){#f2-ott-11-4491}
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###### 

Polymerase chain reaction amplification programs

  Gene         Direction                Primers from 5′ to 3′
  ------------ ------------------------ ------------------------
  *MAGEA1*     Forward                  ATCAACTTCACTCGACAGAGGC
  Reverse      CGGAACAAGGACTCCAGGATAC   
  *MAGEA10*    Forward                  GTCCAAGCACCCTACAGGTC
  Reverse      TTCTGCCTTTGTGATCGGCT     
  *MAGEB2*     Forward                  GAGCCAGAGTTGTAGCCAGG
  Reverse      AGACCTCATTGGGGGTGAGA     
  *KKLC1*      Forward                  ACTGCTTCCCAACTACCAGC
  Reverse      ACACAGAATGCTGCTCGCTA     
  *CTAG1A/B*   Forward                  TGTCCGGCAACATACTGACT
  Reverse      ACTGCGTGATCCACATCAAC     
  β-actin      Forward                  CAGAAGGATTCCTATGTGG
  Reverse      CATGATCTGGGTCATCTTC      

###### 

Patient characteristics

  Variables      n    \%
  -------------- ---- ------
  Gender              
   Male          26   68.4
   Female        12   31.6
  Age (years)         
   \<60          24   63.2
   ≥60           14   36.8
  Smoking             
   Never         12   31.6
   Ever          26   68.4
  T stage             
   T1 or 2       32   84.2
   T3 or 4       6    15.8
  N stage             
   N0            18   47.4
   N1 or 2       20   52.6
  TNM                 
   I             14   36.8
   II or III     24   63.2
  Pathology           
   ADC           19   50.0
   SCC           13   34.2
   Others        6    15.8
  Chemotherapy        
   Yes           16   42.1
   No            22   57.9
  Radiotherapy        
   Yes           3    7.9
   No            35   92.1

**Abbreviations:** ADC, adenocarcinoma; SCC, squamous cell carcinoma.

###### 

Correlation between CTAs expression at mRNA level and clinicopathological features

  Variables     *MAGEA1*    *MAGEA10*   *MAGEB2*    *KK-LC-1*   *CTAG1A/B*                                                                                                              
  ------------- ----------- ----------- ----------- ----------- ------------ ----------- ----------- ---------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  Gender                                0.289                                0.689                              1.000                               0.296                               1.000
   Male         9 (34.6)    17 (65.4)               21 (80.8)   5 (19.2)                 20 (76.9)   6 (23.1)               8 (30.8)    18 (69.2)               18 (69.2)   8 (30.8)    
   Female       7 (58.3)    5 (41.7)                9 (75.0)    3 (25.0)                 9 (75.0)    3 (25.0)               6 (50.0)    6 (50.0)                8 (66.7)    4 (33.3)    
  Age (years)                           0.187                                0.216                              0.115                               0.298                               **0.027**
   \<60         8 (33.3)    16 (66.7)               17 (70.8)   7 (29.2)                 16 (66.7)   8 (33.3)               7 (29.20)   17 (70.8)               13 (54.2)   11 (45.8)   
   ≥60          8 (57.1)    6 (42.9)                13 (92.9)   1 (7.1)                  13 (92.9)   1 (7.1)                7 (50.0)    7 (50.0)                13 (92.9)   1 (7.1)     
  Smoking                               0.713                                0.411                              0.673                               1.000                               0.694
   Never        5 (50.0)    5 (50.0)                7 (70.0)    3 (30.0)                 7 (70.0)    3 (30.0)               4 (40.0)    6 (60.0)                6 (60.0)    4 (40.0)    
   Ever         11 (39.3)   17 (60.7)               23 (82.1)   5 (17.9)                 22 (78.6)   6 (21.4)               10 (35.7)   18 (64.3)               20 (71.4)   8 (28.6)    
  T stage                               1.000                                1.000                              0.613                               0.383                               0.357
   T1--2        14 (43.8)   18 (56.2)               25 (78.1)   7 (21.9)                 25 (78.1)   7 (21.9)               13 (40.6)   19 (59.4)               23 (71.9)   9 (28.1)    
   T3--4        2 (33.3)    4 (66.7)                5 (83.3)    1 (16.7)                 4 (66.7)    2 (33.3)               1 (16.7)    5 (83.3)                3 (50.0)    3 (50.0)    
  N stage                               **0.004**                            **0.016**                          **0.007**                           **0.020**                           0.164
   N0           3 (16.7)    15 (83.3)               11 (61.1)   7 (38.9)                 10 (55.6)   8 (44.4)               3 (16.7)    15 (83.3)               10 (55.6)   8 (44.4)    
   N1--2        13 (65.0)   7 (35.0)                19 (95.0)   1 (5.0)                  19 (95.0)   1 (5.0)                11 (55.0)   9 (45.0)                16 (80.0)   4 (20.0)    
  TNM                                   0.088                                **0.034**                          0.052                               **0.039**                           0.296
   I            3 (21.4)    11 (78.6)               8 (57.1)    6 (42.9)                 8 (57.1)    6 (42.9)               2 (14.3)    12 (85.7)               8 (57.1)    6 (42.9)    
   II + III     13 (45.8)   11 (54.2)               22 (91.7)   2 (8.3)                  21 (87.5)   3 (12.5)               12 (50.0)   12 (50.0)               18 (75.0)   6 (25.0)    
  Pathology                             0.743                                1.000                              1.000                               1.000                               0.728
   ADC          7 (40.0)    12 (60.0)               15 (78.9)   4 (21.1)                 14 (73.7)   5 (26.3)               7 (36.8)    12 (63.2)               12 (63.2)   7 (36.8)    
   None         9 (44.4)    10 (55.6)               15 (78.9)   4 (21.1)                 15 (78.9)   4 (21.1)               7 (36.8)    12 (63.2)               14 (73.7)   5 (26.3)    
   ADC                                                                                                                                                                                  

**Note:**

*P*-value was calculated by Fisher's exact test.

**Abbreviations:** ADC, adenocarcinoma; CTAs, cancer/testis antigens.
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